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AbstrAct
During the last years, there has been a dramatic increase 
in the administrative and bureaucratic burden associated 
with clinical research, which has clearly had an impact 
on its overall efficiency and on the activity of clinical 
investigators and research teams. Indeed, the supervision 
of the adherence of clinical research to Good Clinical 
Practice (GCP) guidelines and legal regulations is of the 
utmost importance. Yet, while such regulations have 
remained largely unchanged during recent years, the 
number of administrative tasks and their complexity have 
grown markedly, as supported by the results of a survey 
performed among 940 clinical investigators that we 
report in this manuscript. Therefore, many investigators 
believe that it has become necessary to undertake a 
rigorous analysis of the causes and consequences of this 
issue, and to create a conduit to channel the advice from 
experienced investigators regarding clinical research 
procedures, in order to improve them. Based on these 
premises, ESMO has launched the ESMO Clinical Research 
Observatory (ECRO), a task force that will analyse different 
aspects of clinical research. ECRO will aim to provide 
the views of ESMO on clinical research procedures 
based on the feedback from clinical investigators, under 
complete adherence to the Declaration of Helsinki, the 
GCP guidelines and any other applicable legal regulations, 
while at the same time showing profound respect for 
all the stakeholders involved in clinical research. This 
manuscript provides the background and rationale for the 
creation of ECRO, its planned activity and an analysis of 
the current administrative burden in clinical research with 
recommendations to rationalise it. Indeed, we expect that 
this effort shall lead to a relevant improvement in the care 
of patients and in the development of clinical research.
 
The only thing that saves us from bureaucracy 
is its inefficiency.
Eugene McCarthy (1916–2005)
Growth of the burden of bureauCraCy in 
CliniCal researCh
In recent years, the administrative and 
bureaucratic burden associated with clinical 
research in Oncology has grown along with 
its clinical success and technical complexity, 
generating a profound impact on the activity 
of investigators and clinical research teams. 
Indeed, regulation and monitoring are 
fundamental to guarantee the safety and 
the rights of patients and the quality of the 
data, according to the high standards that 
characterise clinical research, as defined by 
the Declaration of Helsinki,1 the guidelines 
for Good Clinical Practice (GCP)2 and the 
applicable regional and local legal regula-
tions. Nevertheless, in the current scenario, 
physicians dedicated to clinical research have 
begun to feel overwhelmed by such adminis-
trative tasks, and it has become difficult for 
them to understand the appropriateness 
of certain procedures, to set a limit to the 
amount of time dedicated to administrative 
tasks, or even to perform their clinical role 
with an adequate level of autonomy.
While adherence to the Declaration of 
Helsinki, GCP guidelines and local regula-
tions remains unquestionable, many expe-
rienced investigators believe that their 
overinterpretation and misinterpretation by 
Clinical Research Organisations (CROs), and 
their substitution by their own internal Stan-
dard Operating Procedures have significantly 
increased the administrative burden.3–5 The 
number of processes that need to be docu-
mented and the complexity of the docu-
menting procedures and templates have 
increased dramatically, creating an unsus-
tainable pressure on the investigational site 
staff. Another layer of complexity has been 
added by the incorporation of cumbersome 
online platforms which require intricate 
procedures just to access them, and which 
generate myriads of emails that overwhelm 
the capacity of investigators and research 
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teams. Exhaustive training courses for administrative 
processes, which frequently involve examinations, are 
imposed on clinical research teams to qualify as trial site 
staff. Frequently, such trainings are requested even from 
individuals that are not related to those specific adminis-
trative tasks. The administrative overload even affects the 
medical records of the patients, which are frequently—
and wrongly—considered as the most suitable place to 
document administrative procedures, thus distorting 
their true function. The number of meetings required 
during the development of trials has also increased rele-
vantly, and once again, the focus of such meetings is often 
administrative.
Regrettably, investigators are unable to overcome, or 
even to discuss these situations.3 The appropriateness of 
such procedures is justified by the ‘necessity to comply with 
GCP and legislation’, even though such regulations do not 
usually require such high levels of detail and complexity. 
Yet, the decisions are non- negotiable because the flow of 
communication is unidirectional and does not consider 
other opinions, including those coming from experi-
enced investigators.
neGative impaCt of the inCreased administrative 
burden on investiGators, researCh teams and 
patients
This increased burden of bureaucracy makes poor use 
of the limited time physicians have available, gener-
ating frustration, loss of motivation and complaints from 
experienced investigators3 4 6 as well as decreasing the 
interest of young physicians towards developing a clin-
ical research career. In addition, non- essential adminis-
trative procedures significantly increase the economic 
costs of clinical research and contribute to delays in trial 
implementation,7 thus negatively impacting the flow of 
drug development and hampering patient access to new 
drugs.8 This is particularly relevant in the setting of inde-
pendent academic clinical research,9 which is critical for 
patient- focused drug development.10
More importantly, there is no evidence that this 
increased complexity leads to greater patient safety. A 
relevant example are pharmacovigilance procedures, 
which commonly consist of submitting all the available 
individual serious adverse events to investigators and 
documenting their reception, without any intent to 
summarise, prioritise or classify them. Sometimes, the 
events even include those observed during screening 
periods, when the patient has not yet received the inves-
tigational drug. This leads to an excess of information 
that becomes unmanageable and prevents investigators 
from being effectively updated on the safety of investi-
gational drugs. Another example is the high number of 
informed consent versions generated in some studies 
and their complexity, which are difficult to understand 
by patients,11 and may even generate distrust of the study 
and the research team.
CliniCal interferenCe of protoCols with best mediCal 
praCtiCe
Finally, on limited occasions, discrepancies arise between 
investigators and sponsors or CROs regarding the most 
appropriate clinical management for some patients 
participating in clinical trials. For example, some study 
protocols mandate discontinuation of the study treat-
ments based on the strict application of response criteria, 
disregarding the medical judgement of the investigators 
in clinically complex situations (eg, the possibility of 
maintaining treatment in the case of persistent clinical 
benefit; or to radically treat oligometastatic progressive 
disease while maintaining systemic therapy). Frequently, 
in these situations, the strict interpretation of the protocol 
prevails, generating clinical interference with the best clin-
ical judgement of the physician, who is responsible for 
the care of the patient; and potentially compromising the 
rights, safety and well- being of trial participants, in clear 
contrast with the main goals of the Declaration of Helsinki 
and the GCP guidelines. Conversely, many protocols allow 
physicians to take the final decisions about these complex 
cases, either directly or after discussion with the medical 
coordinator of the study, thus confirming the validity of 
this approach.
esmo survey on the administrative and bureauCratiC 
burden in CliniCal researCh
In order to evaluate the opinions of clinical investiga-
tors on these issues, we developed an online survey that 
was distributed among ESMO members, ESMO faculty, 
oncologists selected for their wide experience in clin-
ical research and investigators attending the ESMO 2019 
meeting in Barcelona. The characteristics of the 940 
responders are presented on table 1 and the responses 
are displayed on table 2.
The results clearly support that there is high agree-
ment among investigators about the excessiveness of 
administrative procedures on clinical research (mean 
score: 8.3 over a 0–10 scale), which they consider an 
obstacle for the development of clinical research (mean 
score: 8.2). The survey also shows wide consensus about 
the feasibility to limit such procedures without compro-
mising the safety and the rights of the patients and the 
quality of the data (mean score: 8.1); and about the 
necessity to incorporate the feedback from physicians 
about the procedures related to clinical research (mean 
score: 8.6). Interestingly, scores were higher among 
oncologists with more than 5 years of experience in clin-
ical research (table 2).
While we acknowledge the limitations of surveys, we 
believe that these results accurately reflect the opinions 
expressed by the vast majority of oncologists dedicated 
to clinical research. Consequently, they should lead 
stakeholders to perform a profound analysis of the 
current situation and to implement the appropriate 
changes.
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Table 1 Characteristics of responders to ESMO survey on the administrative and bureaucratic burden in clinical research
Characteristics
ESMO members 
(n=260)
ESMO faculty 
(n=66)
Oncologists with 
experience in clinical 
research (n=179)
Oncologists attending 
ESMO 2019 (n=435) Overall (n=940)
Years of experience in clinical research (n/%)
  <5 years 54 (21) 2 (3) 19 (11) 175 (40) 250 (27)
  5–10 years 60 (23) 10 (15) 31 (17) 114 (26) 215 (23)
  >10 years 146 (56) 54 (82) 129 (72) 146 (34) 475 (51)
Type of institution (n / %)
  Academic 181 (70) 58 (88) 132 (74) 303 (70) 674 (72)
  Community 66 (25) 6 (9) 40 (22) 113 (26) 225 (24)
  Other 13 (5) 2 (3) 7 (4) 19 (4) 41 (4)
Country (n/%)
  European 203 (78) 59 (89) 177 (99) 221 (51) 660 (70)
  Non- European 57 (22) 7 (11) 2 (1) 214 (49) 280 (30)
Table 2 Results of the ESMO survey on the administrative and bureaucratic burden in clinical research
Statement
Mean score
(0=strongly disagree, 10=strongly agree)
Overall score
(n=940)
Research experience >5 
years (n=690)
The current burden of administrative tasks in clinical research is excessive. 8.3 8.6
Current administrative and bureaucratic procedures in clinical research could 
be reduced without affecting the safety and rights of the patients and the 
quality of the data.
8.2 8.5
Current administrative and bureaucratic procedures represent an obstacle for 
the development of clinical research.
8.1 8.4
It is necessary to incorporate the feedback from physicians about the 
procedures related with clinical research.
8.6 8.8
esmo CliniCal researCh observatory
Based on these premises, ESMO has decided to launch the 
ESMO Clinical Research Observatory (ECRO, https://
www. esmo. org/ research/ esmo- clinical- research- observa-
tory- task- force), a task force developed in 2019, with the 
objective of analysing the procedures of clinical research 
and incorporating the feedback from clinical investiga-
tors, as leaders in the development of research projects 
and those responsible for the care of patients. Indeed, we 
expect that this effort shall lead to an improvement in the 
care of patients and in the efficiency of clinical research.
ECRO will pursue the following areas of development, 
which are summarised in box 1:
1. Rationalisation of the bureaucratic burden associated 
with clinical research, based on strict adherence to cur-
rent legal regulations and to any future amendments, 
and on showing respect to the time and expertise of 
clinical investigators and research teams, who should 
be mainly focused on clinical and research issues. 
Importantly, the ECRO will not enter into a debate 
on which administrative procedures are necessary and 
which are ancillary, but will rather support the follow-
ing recommendations:
a. Limiting the administrative documents required 
for trials to those required by GCP and legal reg-
ulations: We recommend that section 8 of the 
GCP guidelines (‘Essential documents for the conduct 
of a clinical trial’) is strictly followed, and that doc-
uments not included in that section are therefore 
considered non- essential. Of note, GCP guidelines 
only request that a small number of the essential 
documents be signed by the investigator; and they 
consider it “acceptable to combine some of the documents, 
provided the individual elements are readily identifiable” 
(GCP 8.1).
b. Using simplified document templates: For example, 
while GCP guidelines merely—and reasonably—re-
quest that “The investigator should maintain a list of ap-
propriately qualified persons to whom the investigator has 
delegated significant trial- related duties” (GCP 4.1.5), 
most study delegation logs have become extreme-
ly complex and labour- intensive to complete, and 
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box 1 Initial areas of development and methods pursued by 
ECRO.
initial areas of development
1. Rationalisation of the bureaucratic burden associated with clinical 
research:
a. Limiting the administrative documents required for trials to those 
required by GCP and legal regulations.
b. Use simplified document templates.
c. Avoid redundant documentation.
d. Avoid complex electronic resources.
e. Avoid repetitive and unnecessary meetings and control their 
duration.
f. Optimise the delegation of trial procedures from investigators to 
other members of the research team.
2. Avoid the clinical interference of protocols with best medical 
practice.
3. Rationalisation of pharmacovigilance procedures to improve its effi-
ciency and effectiveness.
methods
1. Establish an open channel of communication that allows physicians 
and research teams to deliver their feedback on general or specific 
issues related to clinical research procedures.
2. Foster the generation of data on clinical research procedures.
3. Issue recommendations regarding relevant topics related to clinical 
research.
4. Foster the involvement of experienced clinical investigators in the 
training of study monitors, to provide them with the clinical perspec-
tive of clinical research.
5. Collaborate with other national and international associations relat-
ed to clinical research, especially in the area of Oncology, in order to 
endorse, revise and improve this initiative.
usually the investigator must assume this increased 
complexity. Instead, we recommend the use of sim-
plified templates.
c. Avoid redundant documentation: A relevant exam-
ple is the documentation process of the informed 
consent process. While GCP clearly state that the 
“informed consent is documented by means of a written, 
signed and dated informed consent form” (GCP 1.28),2 it 
has become routine practice to request that investi-
gators duplicate this documentation in the medical 
records, frequently including administrative details, 
such as the version code of the document and so 
on. Such a process is redundant and lacks any value, 
since it is not signed by the patient, as required by 
GCP.
d. Avoid complex electronic resources: Cumbersome 
applications with intricate access procedures should 
be replaced by user- friendly and intuitive systems, 
which should not require unnecessary trainings (ie, 
those dedicated to performing simple procedures, 
such as signing a document; or those dedicated to 
a resource that a particular member of the staff will 
not use). In addition, such resources should rely 
on single access platforms, rather than on multiple 
ones.
e. Avoid repetitive and unnecessary meetings, and 
control their duration: Start- up and monitoring 
meetings should focus on the core aspects of proto-
cols and on clinical issues, and should avoid review-
ing general aspects, ancillary administrative proce-
dures and so on.
f. Optimise the delegation of trial procedures from in-
vestigators to other members of the research team: 
Indeed, the training and preparation of all the 
members of the research teams (ie, data managers, 
research nurses and so on) allows them to assume 
complex responsibilities. Therefore, optimising the 
delegation procedures will facilitate the develop-
ment and monitoring of trials.
2. Avoid the clinical interference of protocols with best 
medical practice: Protocols describe the methodol-
ogy that should be followed to conduct the trial, but 
they cannot foresee the whole variety of individual 
clinical situations that patients undergo and therefore 
they cannot substitute best medical practice. Conse-
quently, protocols should avoid dictating strict and 
non- personalised instructions to manage clinically 
complex situations, such as discontinuation of an an-
ticancer treatment whenever clinical benefit may per-
sist, or when oligometastatic progressive disease may 
be controlled with radical treatment; or deny delivery 
of determined supportive therapy, such as palliative 
radiation. Protocols may consider such events as pro-
gression with regard to the interpretation of the study 
data, but treatment discontinuation should generally 
be decided by the investigators, after thorough discus-
sion with their patients.
Indeed, sponsors’ recommendations regarding 
management of relevant toxicities, based on the 
centralised collection of information, should not be 
considered as clinical interference, particularly in the 
setting of early drug development. Neither should the 
decision to discontinue a study or a specific cohort of a 
study be considered as clinical interference. Neverthe-
less, the sponsor must inform investigators timely to 
avoid miscommunication with patients.
Institutional Review Boards (IRBs) should specifically 
examine the existence of clinical interference in new 
protocols and should carefully review any potential sit-
uation of clinical interference in ongoing protocols, 
requesting appropriate amendments, as required by 
GCP guidelines (GCP 4.5.4).
3. Pharmacovigilance administrative procedures: 
Reporting the safety of medicines in the routine and 
clinical research settings is essential to maintain physi-
cians updated about adverse events, with the objective 
of improving patient safety. In order to increase the 
efficiency and the effectiveness of the process, ECRO 
believes that current logistical and administrative phar-
macovigilance procedures for reporting events from 
the sponsor to the investigators should be thoroughly 
revised and simplified. While the development of the 
optimal process is beyond the scope of this manuscript, 
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and should be defined through the collaboration and 
consensus of all stakeholders, we believe that the cur-
rent practice of unstructured submission of all reports 
on individual serious adverse events to investigators is 
difficult to manage and may even dilute the desired 
effect of proper safety information. Adequate proce-
dures, such as interpreting and periodically summaris-
ing the available information, should be evaluated.
ECRO will employ the following methods to attain its 
objectives (box 1):
1. Establish an open channel of communication that 
allows physicians and research teams to deliver their 
feedback on general or specific issues related to 
clinical research procedures. Relevant issues will be 
addressed by consensus panels including all the stake-
holders of clinical research as appropriate, including 
sponsors, CROs, regulatory authorities and patient 
advocacy groups, in order to find solutions by mutual 
agreement.
2. Foster the generation of data on clinical research pro-
cedures: This includes obtaining balanced feedback 
from investigators through surveys targeting oncolo-
gists, especially ESMO members, reports from expert 
panels and so on; and fostering research and the publi-
cation of studies to characterise common problems re-
lated to clinical research procedures in ESMO publica-
tions, meetings and website. Already existing examples 
include studies that analyse the increasing complexity 
of clinical trials12; the occurrence and causes of exces-
sive delays in starting treatment in cancer patients due 
to centralised molecular testing13–15; the broadening of 
eligibility inclusion criteria in clinical trials, to avoid 
disparities in care16–18; the consequences of outsourc-
ing the monitoring of trials7; the need to simplify in-
formed consents11 and so on.
3. Issue recommendations regarding relevant topics re-
lated to clinical research. Importantly, ECRO will not 
evaluate specific cases, given the regional differences 
in legislations and patient management; and since de-
cisions must depend on the structures that are legal-
ly in place in each country (eg, IRBs and other ethics 
committees). ECRO may contact local scientific societ-
ies to seek their advice about specific regional issues.
4. Foster the involvement of experienced clinical inves-
tigators in the training of study monitors, to provide 
them with the clinical perspective of clinical research.
5. Collaborate with other national and international asso-
ciations related to clinical research, especially those in 
the area of Oncology, in order to endorse, revise and 
improve this initiative.
ConClusions
The ECRO will analyse different aspects of clinical 
research and will provide the views of ESMO on clinical 
research procedures based on the feedback from clinical 
investigators, under complete adherence to the appli-
cable legal regulations, and showing profound respect 
for all the stakeholders involved in clinical research. We 
expect that this effort shall lead to a relevant improve-
ment in the care of patients and in the efficiency of clin-
ical research.
Indeed, we expect that all the stakeholders involved 
in clinical research will recognise the need to critically 
analyse these relevant problems and to assume their 
responsibility in implementing the necessary changes to 
overcome them. Consequently, rather than attempting 
to audit and to control clinical trial procedures, ECRO 
will publicly acknowledge the merits of those entities (ie, 
CROs, sponsors, IRBs, clinical research teams, regulatory 
authorities and so on) who succeed in reviewing and 
simplifying procedures without compromising—or even 
improving—the quality of clinical research, and conse-
quently, the well- being of patients.
We also expect that our fellow physicians will support 
this initiative and that, while fully endorsing the need 
to stringently monitor clinical trials, they will demand 
respect of their time and their expertise and leadership 
in the organisation and completion of research projects 
and clinical care of patients
We would appreciate receiving your comments and opinions 
about this initiative at  ecro@ esmo. org. Please indicate if you 
would allow to make your comment public (ie, on the ESMO web 
page), and in such case, if you would prefer to include your name 
or not.
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